With the success of our 1st virtual event in 2020, it is our pleasure to announce our 32nd Annual, and 2nd virtual, Cancer Progress Conference.
With the success of our first virtual conference, we are looking to expand to three days and are considering adding a partnering component. Join us for 3 days of insightful discussion, vigorous debate and generous networking at the 32nd annual Cancer Progress Conference May 4-6.
Climbing the Highest Peak: Targeting PD-1/L1 Failures in Solid Tumors
Multifunctional Soluble Biologics: Binders, Binders Everywhere
Tumor Agnostic Development
Accelerated Development Paths
Endogenous Reprogramming: Anything One Can Do Ex Vivo, Can One Do In Vivo (and Do Better)?
Allogeneic Cell Therapy: Stocking the Shelf Part I (NKs, NKTs)
Allogeneic Cell Therapy: Stocking the Shelf Part II (Traditional T-cells, Gamma-deltas)
Cell Therapy in Solid Tumors: Freedom of the Open Road
Validating New Platforms: Clinical Pain, Commercial Gain
Counterpoint to Engineered Platforms: Less is More
Investing in the Emerald City of Oncology Innovation: Platforms & Modalities & Targets, Oh My!
Heme Malignancies Transformed: An Idiosyncratic Comparison of Multiple Myeloma and AML
Let’s Make a Deal in Oncology: What’s Behind the Doors & Who Has the Keys? Value Panel
Battle of the Modalities- The sequel
We are incredibly grateful for the donations we received during Cancer Progress 2020. With your help we raised close to $20,000 and donated to:
The US Forecaster’s Check List for Japan: A World of Difference
Expanding the valuation of a biopharmaceutical asset to Japan requires a new mindset in nearly every input of forecasting, with many pitfalls. Doug Willson, Senior Vice President, Cello Health Advantage and Tiffany Ahlers, Chief Commercial Officer, Mycovia Pharmaceuticals Inc., share a checklist to improve the rigor and validity of product forecasts for Japan.
Using organic and unfiltered social media data, Cello Health is proud to share with you the first in a series of reports aimed at centralizing and amplifying the authentic patient experience.
Embedding patient journeys into clinical and commercial planning, for more focused decisions and improved patient outcomes.
The journey to scientific and commercial success is often complex and always critical, if you are looking for an expert partner to help steer you to confident solutions, contact us todayContact us